Jimlig SB 130 Capsule contains Itraconazole 130 mg, a broad-spectrum triazole antifungal agent used for the treatment of various fungal infections. Itraconazole works by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting cell membrane integrity and leading to fungal cell death. This medication is indicated for the management of systemic and superficial mycoses, including aspergillosis, histoplasmosis, blastomycosis, onychomycosis, and candidiasis. Jimlig SB 130 Capsule is particularly effective against infections caused by dermatophytes, yeasts, and molds. It is administered orally and exhibits good bioavailability when taken with food, ensuring optimal absorption. The drug undergoes hepatic metabolism primarily via the cytochrome P450 system and has a relatively long half-life, allowing for convenient dosing schedules. Common adverse effects include gastrointestinal disturbances such as nausea, vomiting, and abdominal pain, as well as potential hepatotoxicity; therefore, liver function monitoring is recommended during prolonged therapy. Caution is advised when co-administered with drugs metabolized by CYP3A4 due to potential drug interactions. Jimlig SB 130 Capsule should be used under medical supervision with appropriate diagnostic confirmation of fungal infection to ensure efficacy and safety.